menu

Treating Obesity as a Chronic Disease

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Treating Obesity as a Chronic Disease

1.00 credits
60 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Experts review guideline-recommended criteria for diagnosis and treatment of obesity and describe best practices for prioritization of obesity management. Tune in to learn more with Dr. Caroline Apovian, Co-Director at Center for Weight Management and Wellness at Brigham and Women’s Hospital in Boston, Dr. Donna Ryan, Professor Emerita at Pennington Biomedical Research Center in Baton Rouge, Louisiana, and Dr. Susan M. Tiso, Retired Family Nurse Practitioner from Family Medicine at the University of California, Irvine.

  • Disclosure of Conflicts of Interest

    Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

    Primary Author

    Caroline Apovian, MD
    Member of the Faculty
    Endocrinology, Diabetes, and Hypertension
    Harvard Medical School
    Co-Director
    Center for Weight Management and Wellness
    Brigham and Womens Hospital
    Boston, Massachusetts

    Caroline Apovian, MD: consultant/advisor/speaker: Altimmune, Inc., Currax Pharmaceuticals, Gelesis, Srl., L-Nutra, Inc., NeuroBo Pharmaceuticals Inc., Novo Nordisk, Inc., Pain Script Corporation, ReShape Lifesciences Inc., Xeno Biosciences.

    Donna Ryan, MD
    Professor Emerita
    Pennington Biomedical Research Center
    Baton Rouge, Louisiana

    Donna H. Ryan,MD: advisor: Altimmune, Amgen, Biohaven, Boeringer Ingelheim, Calibrate, Carmot, Epitomee, Gila Therapeutics, Lilly, Novo Nordisk, Scientific Intake, Structure Tx, Xeno, YSOPIA, Zealand; speaker: IFA Celtic, Novo Nordisk, Lilly; individual publicly traded stock/stock options: Epitomee, Calibrate, Ro, Scientific Intake, Xeno; clinical trial: Novo Nordisk; data safety monitoring board: IQVIA (Rhythm), Lilly.

    Susan M. Tiso, DNP, APRN, FNP-BC, FAANP
    Clinical Professor, Retired
    Sue & Bill Gross School of Nursing
    Family Nurse Practicioner, Retired
    Family Medicine
    University of California, Irvine
    Irvine, California

    Susan Tiso, DNP, APRN, FNP-BC, has no relevant financial relationships to disclose.

    The planners and content peer reviewers from Clinical Care Options, LLC, ProCE, LLC, Practicing Clinicians Exchange, and Q Synthesis have no relevant financial relationships to disclose.

  • Target Audience

    This activity is intended for a broad audience of interprofessional healthcare professionals who provide care, education, and counseling for patients with obesity including primary care physicians, nurse practitioners, physician associates/physician assistants, and pharmacists.  

  • Learning Objectives

    Upon completion of this activity, learners should be able to:

    • Incorporate processes to improve identification and prioritization of weight loss in patients with obesity
    • Evaluate patients based on the guideline-recommended criteria for diagnosis and treatment of obesity
  • Goal Statement

    The goal of this initiative is to increase the percentage of adults with obesity who receive guideline recommended obesity care by 15% among participating clinic sites by the conclusion of the project. This will be determined by a series of 4 quality measures. In addition, individual clinic teams participating in the project as QI teams will establish tailored process improvement goals in order to address their local gaps to improve care and patient outcomes.

  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement

     

    In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO), ProCE, LLC, Practicing Clinicians Exchange, and Q Synthesis. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Physician Continuing Medical Education
    CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Nursing Continuing Professional Development
    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

    Continuing Pharmacy Education

     

    CCO designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-23-152-H01-P Type of Activity: Application Upon successfully completing the posttest with a score of 65% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60  days.

    Physician Assistant/Physician Associate Continuing Medical Education
    Clinical Care Options has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until June 8, 2024. PAs should only claim credit commensurate with the extent of their participation.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Disclosure of Unlabed Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Provider(s)/Educational Partner(s)

    Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange; ProCE, LLC; and Q Synthesis

  • Commercial Support

    This activity is supported by an educational grant from Lilly.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Experts review guideline-recommended criteria for diagnosis and treatment of obesity and describe best practices for prioritization of obesity management. Tune in to learn more with Dr. Caroline Apovian, Co-Director at Center for Weight Management and Wellness at Brigham and Women’s Hospital in Boston, Dr. Donna Ryan, Professor Emerita at Pennington Biomedical Research Center in Baton Rouge, Louisiana, and Dr. Susan M. Tiso, Retired Family Nurse Practitioner from Family Medicine at the University of California, Irvine.

  • Disclosure of Conflicts of Interest

    Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

    Primary Author

    Caroline Apovian, MD
    Member of the Faculty
    Endocrinology, Diabetes, and Hypertension
    Harvard Medical School
    Co-Director
    Center for Weight Management and Wellness
    Brigham and Womens Hospital
    Boston, Massachusetts

    Caroline Apovian, MD: consultant/advisor/speaker: Altimmune, Inc., Currax Pharmaceuticals, Gelesis, Srl., L-Nutra, Inc., NeuroBo Pharmaceuticals Inc., Novo Nordisk, Inc., Pain Script Corporation, ReShape Lifesciences Inc., Xeno Biosciences.

    Donna Ryan, MD
    Professor Emerita
    Pennington Biomedical Research Center
    Baton Rouge, Louisiana

    Donna H. Ryan,MD: advisor: Altimmune, Amgen, Biohaven, Boeringer Ingelheim, Calibrate, Carmot, Epitomee, Gila Therapeutics, Lilly, Novo Nordisk, Scientific Intake, Structure Tx, Xeno, YSOPIA, Zealand; speaker: IFA Celtic, Novo Nordisk, Lilly; individual publicly traded stock/stock options: Epitomee, Calibrate, Ro, Scientific Intake, Xeno; clinical trial: Novo Nordisk; data safety monitoring board: IQVIA (Rhythm), Lilly.

    Susan M. Tiso, DNP, APRN, FNP-BC, FAANP
    Clinical Professor, Retired
    Sue & Bill Gross School of Nursing
    Family Nurse Practicioner, Retired
    Family Medicine
    University of California, Irvine
    Irvine, California

    Susan Tiso, DNP, APRN, FNP-BC, has no relevant financial relationships to disclose.

    The planners and content peer reviewers from Clinical Care Options, LLC, ProCE, LLC, Practicing Clinicians Exchange, and Q Synthesis have no relevant financial relationships to disclose.

  • Target Audience

    This activity is intended for a broad audience of interprofessional healthcare professionals who provide care, education, and counseling for patients with obesity including primary care physicians, nurse practitioners, physician associates/physician assistants, and pharmacists.  

  • Learning Objectives

    Upon completion of this activity, learners should be able to:

    • Incorporate processes to improve identification and prioritization of weight loss in patients with obesity
    • Evaluate patients based on the guideline-recommended criteria for diagnosis and treatment of obesity
  • Goal Statement

    The goal of this initiative is to increase the percentage of adults with obesity who receive guideline recommended obesity care by 15% among participating clinic sites by the conclusion of the project. This will be determined by a series of 4 quality measures. In addition, individual clinic teams participating in the project as QI teams will establish tailored process improvement goals in order to address their local gaps to improve care and patient outcomes.

  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement

     

    In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO), ProCE, LLC, Practicing Clinicians Exchange, and Q Synthesis. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Physician Continuing Medical Education
    CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Nursing Continuing Professional Development
    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

    Continuing Pharmacy Education

     

    CCO designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-23-152-H01-P Type of Activity: Application Upon successfully completing the posttest with a score of 65% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60  days.

    Physician Assistant/Physician Associate Continuing Medical Education
    Clinical Care Options has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until June 8, 2024. PAs should only claim credit commensurate with the extent of their participation.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Disclosure of Unlabed Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Provider(s)/Educational Partner(s)

    Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange; ProCE, LLC; and Q Synthesis

  • Commercial Support

    This activity is supported by an educational grant from Lilly.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule22 May 2024